Merck & Co., Inc.
As of Oct 22, 2026 close
- Market cap
- $363.68B
- P/E (TTM)
- 114.62
- Forward P/E
- 230.35
- Dividend yield
- 2.31%
- 52-week range
- $82.01$156.92
- Volume (live)
- -
- Avg. volume (3M)
- 9.87M
Merck & Co. (MRK) Stock Price & Financial Analysis
Merck & Co. Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $144.07 - $154.02 |
|---|---|
| 52-Week High | $156.92 |
| 52-Week Low | $82.01 |
| Open | $151.05 |
| Volume (last close) | 19.03M |
| Average Volume (3M) | 9.87M |
| Revenue (TTM) | 66.49B |
|---|---|
| Net Income (TTM) | 3.17B |
| Free Cash Flow (TTM) | 16.06B |
| EPS (TTM) | $1.28 |
| Profit Margin | 4.77% |
| Operating Margin | 13.29% |
| Return on Equity (ROE) | 7.56% |
| Debt to Equity | 1.28 |
| Annual Dividend | $3.40 |
|---|---|
| Dividend Yield | 2.31% |
| Payout Ratio | 200.00% |
| Last Dividend Ex-Date | Sep 15, 2026 |
| Market Cap | 363.68B |
|---|---|
| Shares Outstanding | 2.47B |
| P/E Ratio (TTM) | 114.62 |
| Forward P/E | 230.35 |
| Price to Sales (P/S) | 5.47 |
| Price to Book (P/B) | 8.66 |
| EV/EBITDA | 17.43 |
| 50-Day MA | $145.77 |
|---|---|
| 200-Day MA | $125.27 |
| 1-Year Change | +68.89% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Merck & Co. at a Glance
As of the Oct 22, 2026 close, Merck & Co. (MRK) has a market capitalization of $363.68B. The stock trades at 114.6× trailing earnings, 230.3× forward earnings and 5.5× sales. Over the trailing twelve months it earned $3.17B on revenue of $66.49B (a 4.8% profit margin) and generated $16.06B of free cash flow. Revenue grew 4.5% year over year.
As of its latest reported balance sheet, it holds $6.85B in cash and securities against $53.91B of debt, a net debt position of $47.06B.
Merck & Co. pays a quarterly dividend totaling $3.40 per share a year, a 2.31% yield at the Oct 22, 2026 close, with 15 consecutive years of dividend increases.
The share price is up 68.9% over the past year. At $147.24 (the Oct 22, 2026 close) it sits near the top of its 52-week range of $82.01 to $156.92, above its 200-day moving average of $125.27.
Based on 27 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $160.00, 8.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Merck & Co.
What is the current stock price for MRK?
As of the Oct 22, 2026 close, MRK stock trades at $147.24. The 52-week range is $82.01–$156.92, with a day range of $144.07–$154.02.
What is the P/E ratio for MRK?
As of the Oct 22, 2026 close, Merck & Co.'s trailing twelve-month (TTM) P/E ratio is 114.6, meaning investors pay $114.6 for every $1 of annual earnings. The forward P/E is 230.3, reflecting analyst expectations for future earnings. Merck & Co. operates in the Healthcare sector.
Does MRK pay dividends?
Yes, Merck & Co. pays a 2.31% annual dividend yield as of the Oct 22, 2026 close ($3.40 per share a year). The trailing twelve-month payout ratio is 200.0%. The most recent ex-dividend date was September 15, 2026.
What do analysts recommend for MRK?
Based on ratings from 27 professional analysts over the last 90 days, the consensus for MRK is Buy. The average 12-month price target is $160.00, a 8.7% upside from the Oct 22, 2026 close of $147.24.
What is the market cap of MRK?
As of the Oct 22, 2026 close, Merck & Co.'s market capitalization is $363.68B, classifying it as a mega-cap company. Merck & Co. operates in the Healthcare sector within the Drug Manufacturers - General industry.